Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab
Pizzatti, LauraFirst
Writing - Original Draft Preparation
;Mugheddu, CristinaSecond
Data Curation
;Sanna, SilviaMember of the Collaboration Group
;Atzori, Laura
Penultimate
Writing - Review & Editing
;Rongioletti, FrancoLast
Supervision
2020-01-01
Abstract
Erythrodermic psoriasis is a severe, life-threatening condition with additional complications, when occurring in hemodialyzed patients, as the majority of treatments are contraindicated. A 44-years-old man, of Philippine origins, with a 15-years-history of psoriasis treated with cyclosporine developed progressive hypertension and renal insufficiency. Despite drug dismission, renal function worsen to end-stage, and hemodialysis was necessary three times a week. Phototherapy was not able to control the skin condition, progressing to erythroderma, and after nephrology consultation, the patient consent to the off-label secukinumab treatment, at the standard regimen (300 mg subcutaneously once weekly at weeks 0-4 followed by 300 mg every 4 weeks). Seven days after the first injection, a rapid improvement was noted, with the psoriasis area severity index (PASI) score passing from 31.5 to 17.6. At the 52-week-follow-up visit, the patient was completely clarified, without any side effects. The case supports secukinumab effectiveness and safety in difficult patients, including erythrodermic psoriasis with end-stage renal failure, as drug plasma levels seem not to be affected by hemodialysis. Results are rapidly achieved, and long term maintained, with the additional advantage of a very comfortable monthly administration.File | Size | Format | |
---|---|---|---|
secukinumab Eritrodermic psoriasis emodialisidth.13348.pdf Solo gestori archivio
Type: versione post-print
Size 2.26 MB
Format Adobe PDF
|
2.26 MB | Adobe PDF | & nbsp; View / Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.